The White House has reportedly reached a deal with pharmaceutical companies to lower the prices of weight-loss drugs, including GLP-1 drugs. The deal, which involves companies such as Novo Nordisk and Lilly, is expected to result in significant savings, with some reports suggesting $529 billion in savings over 10 years. The agreement appears to be part of a larger effort to expand most-favored-nation (MFN) deals with pharmaceutical companies to reduce drug prices for Americans, including those on Medicare.